The safety and efficacy of the biosimilar anti-CD20 antibody, Truxima, in haematological malignancy

被引：0
|
作者：
Lo, I. [1 ]
Bansal, S. [1 ]
Arami, S. [1 ]
机构：
[1] London Northwest Healthcare NHS Trust, London, England
来源：
LEUKEMIA RESEARCH | 2018年 / 73卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PP-48
引用
收藏
页码：S51 / S51
页数：1
相关论文
共 50 条
  • [41] Anti-CD20 in lupus
    Isenberg, DA
    Leandro, MJ
    Ehrenstein, MR
    Edwards, JCW
    Manson, J
    Cambridge, G
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 27 - 28
  • [42] Efficacy of Rituximab, an Anti-CD20 Antibody for Preventing Hemolysis Due to Passenger Leucocyte Syndrome (PLS).
    Tsujimura, K.
    Ishida, H.
    Toki, D.
    Nozaki, T.
    Omoto, K.
    Shimizu, T.
    Tanabe, K.
    TRANSPLANTATION, 2014, 98 : 617 - 617
  • [43] Efficacy of Rituximab, an Anti-CD20 Antibody for Preventing Hemolysis Due to Passenger Leucocyte Syndrome (PLS)
    Tsujimura, K.
    Ishida, H.
    Toki, D.
    Nozaki, T.
    Omoto, K.
    Shimizu, T.
    Tanabe, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 617 - 617
  • [44] INTRACELLULAR CALCIUM AND METABOLISM HAVE CRITICAL ROLES IN DETERMINING ANTI-CD20 ANTIBODY EFFICACY IN DLBCL
    Vilventhraraja, E.
    Gribben, J.
    Braun, A.
    HAEMATOLOGICA, 2017, 102 : 567 - 567
  • [45] Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
    Mitchell R Smith
    Oncogene, 2003, 22 : 7359 - 7368
  • [46] Combination therapy with the type II anti-CD20 antibody obinutuzumab
    Klein, Christian
    Bacac, Marina
    Umana, Pablo
    Fingerle-Rowson, Gunter
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (10) : 1145 - 1162
  • [47] The use of rituximab, anti-CD20 monoclonal antibody, in pediatric transplantation
    Pescovitz, MD
    PEDIATRIC TRANSPLANTATION, 2004, 8 (01) : 9 - 21
  • [48] The Labelling of Monoclonal Antibody Anti-CD20 with Yttrium and Lutetium Radionuclides
    Budsky, Frantisek
    Miler, Vlastimil
    Malek, Zdenek
    CHEMICKE LISTY, 2009, 103 (01): : 76 - 80
  • [49] Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation
    Tallantyre, E. C.
    Whittam, D. H.
    Jolles, S.
    Paling, D.
    Constantinesecu, C.
    Robertson, N. P.
    Jacob, A.
    JOURNAL OF NEUROLOGY, 2018, 265 (05) : 1115 - 1122
  • [50] Rituximab, an anti-CD20 monoclonal antibody: History and mechanism of action
    Pescovitz, MD
    AMERICAN JOURNAL OF TRANSPLANTATION, 2006, 6 (05) : 859 - 866
12345